Trevi Therapeutics Stock Debt To Equity
| TRVI Stock | USD 2.88 0.04 1.37% |
Trevi Therapeutics fundamentals help investors to digest information that contributes to Trevi Therapeutics' financial success or failures. It also enables traders to predict the movement of Trevi Stock. The fundamental analysis module provides a way to measure Trevi Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Trevi Therapeutics stock.
| Last Reported | Projected for Next Year |
Trevi | Debt To Equity |
Trevi Therapeutics Company Debt To Equity Analysis
Trevi Therapeutics' Debt to Equity is calculated by dividing the Total Debt of a company by its Equity. If the debt exceeds equity of a company, then the creditors have more stakes in a firm than the stockholders. In other words, Debt to Equity ratio provides analysts with insights about composition of both equity and debt, and its influence on the valuation of the company.
Current Trevi Therapeutics Debt To Equity | 0.21 % |
Most of Trevi Therapeutics' fundamental indicators, such as Debt To Equity, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Trevi Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Trevi Debt To Equity Driver Correlations
Understanding the fundamental principles of building solid financial models for Trevi Therapeutics is extremely important. It helps to project a fair market value of Trevi Stock properly, considering its historical fundamentals such as Debt To Equity. Since Trevi Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Trevi Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Trevi Therapeutics' interrelated accounts and indicators.
Click cells to compare fundamentals
High Debt to Equity ratio typically indicates that a firm has been borrowing aggressively to finance its growth and as a result may experience a burden of additional interest expense. This may reduce earnings or future growth. On the other hand a small D/E ratio may indicate that a company is not taking enough advantage from financial leverage. Debt to Equity ratio measures how the company is leveraging borrowing against the capital invested by the owners.
| Competition |
Trevi Total Stockholder Equity
Total Stockholder Equity |
|
According to the company disclosure, Trevi Therapeutics has a Debt To Equity of 0.206%. This is 99.62% lower than that of the Pharmaceuticals sector and 98.94% lower than that of the Health Care industry. The debt to equity for all United States stocks is 99.58% higher than that of the company.
Trevi Debt To Equity Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Trevi Therapeutics' direct or indirect competition against its Debt To Equity to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Trevi Therapeutics could also be used in its relative valuation, which is a method of valuing Trevi Therapeutics by comparing valuation metrics of similar companies.Trevi Therapeutics is currently under evaluation in debt to equity category among its peers.
Trevi Therapeutics Current Valuation Drivers
We derive many important indicators used in calculating different scores of Trevi Therapeutics from analyzing Trevi Therapeutics' financial statements. These drivers represent accounts that assess Trevi Therapeutics' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Trevi Therapeutics' important valuation drivers and their relationship over time.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Market Cap | 44.0M | 43.7M | 17.9M | 124.6M | 132.7M | 139.3M | |
| Enterprise Value | (12.9M) | 12.9M | (4.3M) | 121.2M | 101.6M | 64.4M |
Trevi Therapeutics ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Trevi Therapeutics' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Trevi Therapeutics' managers, analysts, and investors.Environmental | Governance | Social |
Trevi Fundamentals
| Return On Equity | -0.6 | ||||
| Return On Asset | -0.37 | ||||
| Current Valuation | 159.3 M | ||||
| Shares Outstanding | 76.87 M | ||||
| Shares Owned By Insiders | 1.18 % | ||||
| Shares Owned By Institutions | 80.60 % | ||||
| Number Of Shares Shorted | 1.72 M | ||||
| Price To Book | 3.79 X | ||||
| EBITDA | (33.8 M) | ||||
| Net Income | (29.07 M) | ||||
| Cash And Equivalents | 77.86 M | ||||
| Cash Per Share | 1.82 X | ||||
| Total Debt | 1.34 M | ||||
| Debt To Equity | 0.21 % | ||||
| Current Ratio | 5.18 X | ||||
| Book Value Per Share | 0.78 X | ||||
| Cash Flow From Operations | (31.71 M) | ||||
| Short Ratio | 3.78 X | ||||
| Earnings Per Share | (0.44) X | ||||
| Target Price | 9.11 | ||||
| Number Of Employees | 27 | ||||
| Beta | 1.01 | ||||
| Market Capitalization | 224.45 M | ||||
| Total Asset | 89.4 M | ||||
| Retained Earnings | (239.13 M) | ||||
| Working Capital | 81.72 M | ||||
| Net Asset | 89.4 M |
About Trevi Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Trevi Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Trevi Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Trevi Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
When determining whether Trevi Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Trevi Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Trevi Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Trevi Therapeutics Stock:Check out Trevi Therapeutics Piotroski F Score and Trevi Therapeutics Altman Z Score analysis. For more detail on how to invest in Trevi Stock please use our How to Invest in Trevi Therapeutics guide.You can also try the Equity Analysis module to research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Trevi Therapeutics. If investors know Trevi will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Trevi Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.44) | Return On Assets (0.37) | Return On Equity (0.60) |
The market value of Trevi Therapeutics is measured differently than its book value, which is the value of Trevi that is recorded on the company's balance sheet. Investors also form their own opinion of Trevi Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Trevi Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Trevi Therapeutics' market value can be influenced by many factors that don't directly affect Trevi Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Trevi Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Trevi Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Trevi Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.